Document Detail


Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study.
MedLine Citation:
PMID:  15499045     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To examine the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity with calcified coronary plaque in young adults. METHODS AND RESULTS: Nested case-control study among CARDIA participants at the year 15 examination (2000 to 2001, 33 to 45 years old). Cases (n=266) were those with and controls (n=266) those without evidence of calcified coronary plaque by computed tomography matched 1:1 on sex and race. Lp-PLA2 mass and activity were significantly higher in cases (296+/-101 ng/mL and 36.4+/-12.3 nmol/mL per minute) than in controls (267+/-80 ng/mL and 32.9+/-11.8 nmol/mL per minute). In age-adjusted conditional logistic regression, the odds ratio (OR) of calcified coronary plaque per 1 standard deviation (SD) increment was 1.40 (95% CI, 1.17 to 1.67) and 1.39 (95% CI, 1.14 to 1.70) for Lp-PLA2 mass and activity, respectively. After adjusting for multiple covariates including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, and C-reactive protein, a statistically significant association remained for Lp-PLA2 mass (OR, 1.28; 95% CI, 1.03 to 1.60) but not for activity (OR, 1.09; 95% CI, 0.84 to 1.42). No evidence was found for interaction between Lp-PLA2 mass or activity with LDL-C as predictors of calcified coronary plaque. CONCLUSIONS: An independent association of Lp-PLA2 mass with calcified coronary plaque existed in young adults. Therefore, Lp-PLA2 mass may be a useful marker of subclinical cardiovascular risk.
Authors:
Carlos Iribarren; Myron D Gross; Jeanne A Darbinian; David R Jacobs; Stephen Sidney; Catherine M Loria
Related Documents :
1644095 - Effect of lovastatin or niacin combined with colestipol and regression of coronary athe...
7674695 - Clinical perspectives on primary and secondary prevention of coronary atherosclerosis.
8517425 - Design and recruitment in the united states of a multicenter quantitative angiographic ...
19080725 - Should we treat all patients with coronary heart disease or the equivalent with statins?
2975215 - Left ventricular hypertrophy and antihypertensive therapy.
11114955 - Structural myocardial changes after coronary artery surgery.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.     Date:  2004-10-21
Journal Detail:
Title:  Arteriosclerosis, thrombosis, and vascular biology     Volume:  25     ISSN:  1524-4636     ISO Abbreviation:  Arterioscler. Thromb. Vasc. Biol.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2004-12-31     Completed Date:  2005-08-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9505803     Medline TA:  Arterioscler Thromb Vasc Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  216-21     Citation Subset:  IM    
Affiliation:
Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA, USA. cgi@dor.kaiser.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
1-Alkyl-2-acetylglycerophosphocholine Esterase
Adult
Calcinosis / blood,  complications*,  enzymology
Calcium / blood
Case-Control Studies
Coronary Artery Disease / blood,  complications*,  enzymology
Female
Humans
Male
Middle Aged
Phospholipases A / blood*,  metabolism*
Phospholipases A2
Time
Grant Support
ID/Acronym/Agency:
1R01-HL53560-01A1/HL/NHLBI NIH HHS; N01-HC-48047/HC/NHLBI NIH HHS; N01-HC-48048/HC/NHLBI NIH HHS; N01-HC-48049/HC/NHLBI NIH HHS; N01-HC-48050/HC/NHLBI NIH HHS
Chemical
Reg. No./Substance:
7440-70-2/Calcium; EC 3.1.1.-/Phospholipases A; EC 3.1.1.4/Phospholipases A2; EC 3.1.1.47/1-Alkyl-2-acetylglycerophosphocholine Esterase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ACAT1 deficiency disrupts cholesterol efflux and alters cellular morphology in macrophages.
Next Document:  Acyl-coenzymeA (CoA):cholesterol acyltransferase inhibition in rat and human aortic smooth muscle ce...